DHDavid L. Hudson

David L. Hudson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David L. Hudson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher J. Shepherd

    Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK

    2 shared publications
  • Gerhardt Attard

    UCL Cancer Institute, University College London, London, UK

    2 shared publications
  • John R. Masters

    The Prostate Cancer Research Centre, Institute of Urology, University College London, 67 Riding House Street, London W1W 7EJ, UK

    2 shared publications
  • Michael J. O'HAre

    Department of Surgery, University College London, 67 Riding House Street, London W1W 7EJ, UK

    2 shared publications
  • Siân Rizzo

    Prostate Stem Cell Laboratory, Institute of Cancer Research, Sutton, Surrey, UK

    2 shared publications
  • Tahirah N. Alam

    The Prostate Cancer Research Centre, Institute of Urology, University College London, 67 Riding House Street, London W1W 7EJ, UK

    2 shared publications

Latest Publications

  • Expression profiling of CD133+ and CD133— epithelial cells from human prostate

    by Christopher J. Shepherd, Siân Rizzo, Ioanna Ledaki, Melissa Davies, Daniel Brewer, Gerhardt Attard, Johann de Bono, David L. Hudson

    BACKGROUND: Recent evidence suggests that prostate stem cells in benign and tumor tissue express the cell surface marker CD133, but these cells have not been well characterized. The aim of our study was to gene expression profile CD133‐expressing cells.METHODS: We analyzed CD133‐positive (CD133+) and ‐negative (CD133−) sub‐populations of high‐integrin expressing epithelial cells isolated from benign human prostate tissue and hormone‐refractory prostate cancer (HRPC).RESULTS: CD133+ cells freshly isolated from benign prostate tissue exhibited an expression profile characteristic of a putative stem/progenitor cell population, with transcripts involved in biological processes ranging from development and ion homeostasis to cell communication. The profile of CD133− cells was consistent with that of a transit amplifying population, suggesting up‐regulated proliferation and metabolism. Comparison of benign populations to those from HRPC showed some similarities between CD133+ profiles but also revealed significant differences that provide a tumor‐specific pattern, which included evidence of increased metabolic activity and active proliferation. Subsequently, we demonstrated protein expression of a number of candidate genes in these cell populations and in benign tissue. In a novel observation we also found expression of some of these markers in prostate tumors, including the oligodendrocyte lineage transcription factor OLIG1.CONCLUSIONS: This study provides a unique genome‐wide molecular signature of CD133+ and CD133− human prostate epithelial cells. This will provide a valuable resource for prostate stem cell biology research and the identification of novel therapeutic targets for the treatment of prostate cancer. Prostate 68:1007–1024, 2008.


  • A conditionally immortalized cell line model for the study of human prostatic epithelial cell differentiation

    by Bernadette Daly-Burns, Tahirah N. Alam, Alan Mackay, Jeremy Clark, Christopher J. Shepherd, Siân Rizzo, Roger Tatoud, Michael J. O'HAre, John R. Masters, David L. Hudson


  • Prostate epithelial stem cells

    by S. Rizzo, G. Attard, D. L. Hudson

    Abstract.  The prostate gland is the site of the most commonly diagnosed cancer in men in USA and UK, accounting for one in five of new cases of male cancer. Common with many other cancer types, prostate cancer is believed to arise from a stem cell that shares characteristics with the normal stem cell. Normal prostate epithelial stem cells were recently identified and found to have a basal cell phenotype together with expression of CD133. Preliminary data have now emerged for a prostate cancer stem cell that also expresses cell surface CD133 but lacks expression of the androgen receptor. Here we examine the evidence supporting the existence of prostate cancer stem cells and discuss possible mechanisms of stem cell maintenance.


  • Epithelial stem cells in human prostate growth and disease

    by D L Hudson

    Benign prostatic hyperplasia and prostate cancer arise as a consequence of changes in the balance between cell division and differentiation. Little, however, is known about the control of this process. Stem cells are a small population of cells that divide occasionally to produce transit-amplifying cells that in turn produce the differentiated cell types of the tissue. It is believed that cancer cell proliferation is also driven by stem cells. We have shown that around one in 200 prostate epithelial cells have characteristics of stem cells and that these cells are contained within a population with a distinct keratin expression pattern. Work is now ongoing to identify markers for these cells that will allow us to study the role they play in prostatic disease.


  • Open Access

    Differential Expression of CD44 During Human Prostate Epithelial Cell Differentiation

    by Tahirah N. Alam, Michael J. O'HAre, István Laczkó, Alex Freeman, Farah Al-Beidh, John R. Masters, David L. Hudson

    CD44 is a polymorphic transmembrane glycoprotein that binds hyaluronan and growth factors. Multiple isoforms of the protein can be generated by alternative splicing but little is known about the expression and function of these isoforms in normal development and differentiation. We have investigated the expression of CD44 during normal prostate epithelial cell differentiation. A conditionally immortalized prostate epithelial cell line, Pre2.8, was used as a model system. These cells proliferate at 33C but at 39C stop dividing and undergo changes consistent with early stages of cell differentiation. During the differentiation of these cells, the expression of the CD44 isoform v3-v10 was upregulated. Two layers of epithelial cells can clearly be distinguished in the human prostate, a basal layer expressing keratins 5/14 and a luminal layer expressing keratins 8/18. In prostate tissue the v3-v10 isoform was found predominantly in basal cells but also in keratin 14-negative, keratin 19-positive cells intermediate between the two layers. CD44 v3-v10 was also expressed in other keratin 14-negative prostate tissues, the ejaculatory ducts and prostatic urethra. Therefore, CD44 v3-v10 may be important as a cell surface marker for differentiating cells in the prostate epithelium.


  • Prostate epithelial stem cell culture

    by David L. Hudson

    The prostate gland is the site of the second most common cancer in men in the UK, with 9,280 deaths recorded in 2000. Another common disease of the prostate is benign prostatic hyperplasia and both conditions are believed to arise as a result of changes in the balance between cell proliferation and differentiation. There are three types of prostatic epithelial cell, proliferative basal, secretory luminal, and neuroendocrine. All three are believed to be derived from a common stem cell through differentiation along different pathways but the mechanisms behind these processes is poorly understood. In particular, there has until recently been very little information about prostate stem cell growth and differentiation. This review will discuss ways of distinguishing these prostate cell types using markers, such as keratins. Methods available for the culture of prostate epithelial cells and for the characterisation of stem cells both in monolayer and three-dimensional models are examined.